Patient-Reported Outcomes: Open-Label Trials Can Be Designed To Minimize Bias, US FDA Says

 
• By Sue Sutter
  
Patient experience data
Even in an open-label trials, patients should be asked about their experience with a cancer drug. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Product Reviews

More from Pink Sheet